84. Trends Cancer. 2018 Jun;4(6):404-407. doi: 10.1016/j.trecan.2018.04.005. Epub2018 May 19.Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors.Nakao M(1), Fujiwara S(2), Iwase H(3).Author information: (1)Department of Medical Cell Biology, Institute of Molecular Embryology andGenetics, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address:mitnakao@kumamoto-u.ac.jp.(2)Department of Breast and Endocrine Surgery, Graduate School of MedicalSciences, Kumamoto University, Kumamoto 860-8556, Japan; Hormone Action andOncogenesis Section, Laboratory of Receptor Biology and Gene Expression, NationalCancer Institute, National Institutes of Health, Bethesda, MD, USA.(3)Department of Breast and Endocrine Surgery, Graduate School of MedicalSciences, Kumamoto University, Kumamoto 860-8556, Japan.Estrogen receptor (ER) α-positive breast cancers frequently acquire resistance toendocrine therapy. However, recent studies found that a fraction of these tumors overexpress ER, and that estrogen treatment induces apoptosis. We propose a'cancer navigation' strategy to systematically lead resistant cells to growtharrest and apoptosis.Copyright © 2018 Elsevier Inc. All rights reserved.DOI: 10.1016/j.trecan.2018.04.005 PMID: 29860984 